Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Lite Strategy Inc Is Focused On The Clinical Development Of Novel Therapies For Cancer. The Company'S Portfolio Of Drug Candidates Includes Voruciclib, An Oral Cyclin-Dependent Kinase 9 (Cdk9) Inhibitor, And Zandelisib, An Oral, Once-Daily, Selective Pi3k Inhibitor. It Is A Clinical-Stage Pharmaceutical Company Committed To The Development Of Novel And Differentiated Cancer Therapies Intended To Improve Outcomes For Patients. The Company Operates In The Segments: Digital Asset Treasury Strategy And Development Of Pharmaceutical Products.